18 July 2019 - - US-based biotechnology company Pandion Therapeutics, Inc has appointed Rahul Kakkar, MD, FACC as chief executive officer and as a member of the company's board of directors, the company said.
Kakkar is a biotech entrepreneur and physician-scientist, most recently serving as a founding executive at Corvidia Therapeutics.
He joins Pandion as the company advances to the development stage and is nearing the clinic with its first antibody candidates.
Kakkar succeeds Anthony J. Coyle, PhD, who is a founder of Pandion, led the company through its early stage, series A funding and development of its R and D strategy, and will be leaving the company in the transition.
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment, while avoiding the systemic immunosuppression of conventional medicines.
The company's proprietary technology platform enables the design of bispecific antibodies with targeting fragments that bind to specific tissues at the local site of inflammatory disease, coupled with effector molecules that modulate immune activity to restore immune homeostasis.
With its robust antibody platform, Pandion is developing a pipeline for autoimmune and inflammatory diseases and transplantation, with an initial focus on diseases of the gastrointestinal tract, liver, kidney, pancreas, and skin.
Pandion was founded in 2017 and is funded by a strong syndicate of venture investors. The company is headquartered in Cambridge, Massachusetts.